Europe — EMA
Ontozry (Cenobamate)
Cenobamate, the active ingredient in Ontozry, is a novel antiepileptic presented as a tablet for oral use. It is indicated for the treatment of partial-onset seizures in adults.
Request sourcing
What is Cenobamate?
Cenobamate, the active ingredient in Ontozry, is a novel antiepileptic presented as a tablet for oral use. It is indicated for the treatment of partial-onset seizures in adults. GNH USA supplies Ontozry as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
GNH USA supplies Ontozry as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
What is Cenobamate used for?
Ontozry is an antiepileptic drug that targets the seizure‑control pathway in patients with epilepsy. - Partial seizures: Reduces the frequency of seizures experienced. - Adjunct therapy: Enhances seizure control when added to existing antiepileptic regimens. - Monotherapy : Provides t t t t t.
What are the side effects of Cenobamate?
Common ....
What precautions apply to Cenobamate?
...
